Genetics and Heart Health After Cancer Therapy

CompletedOBSERVATIONAL
Enrollment

79

Participants

Timeline

Start Date

December 5, 2017

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
Breast CancerHereditary Breast/Ovarian Cancer (brca1, Brca2)Heart DiseasesDrug-Induced Cardiomyopathy
Interventions
DIAGNOSTIC_TEST

echocardiography

Resting echocardiograms (Vivid E9 or E95, GE Healthcare) with conventional measures of systolic and diastolic function, in conjunction with posthoc quantitation of novel measures of strain and strain rate will be obtained at each study time point.

OTHER

Cardiopulmonary Exercise Testing

A cardiopulmonary exercise test (CPET, also called V02 test) will be completed at each study time point utilizing a standard clinical protocol, on either a stationary bike or treadmill. The purpose of this test is to estimate maximal oxygen consumption (V02 max) as in index of cardiopulmonary fitness. Resting ECG, heart rate, and BP will be obtained prior to beginning the test, during each stage of the test and for 5 minutes after the test is stopped.

OTHER

Blood Collection

We will obtain blood samples (approximately 16mL) at baseline and (approximately 12mL) at each follow-up visit. Typically these will be drawn via peripheral venipuncture, however if patients have a port-a-cath in place, blood may be drawn from the port instead.

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT03510689 - Genetics and Heart Health After Cancer Therapy | Biotech Hunter | Biotech Hunter